Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 23/03/2020 | Notification of Lapse of Unlisted Options | Download |
| 20/03/2020 | Notification of Expiry of Unlisted Options | Download |
| 18/03/2020 | Phase II Bisantrene Trial Recruitment Completed | Download |
| 13/03/2020 | Appendix 2A | Download |
| 13/03/2020 | Cleansing Notice | Download |
| 12/03/2020 | Appendix 2A-Completion of Placement | Download |
| 12/03/2020 | Cleansing Notice | Download |
| 11/03/2020 | Becoming a substantial holder | Download |
| 11/03/2020 | Change in substantial holding | Download |
| 11/03/2020 | Appendix 3Y-William Garner | Download |
ASX: RAC
Price
Latest News
Prof. Didier Blaise joins Clinical Advisory Board
Race is pleased to announce the appointment of Professor Didier Blaise to the Clinical Advisory
Race raises A$1.8 million, appoints Non-Executive Chairman
Race has received firm commitments for A$1.8 million (before costs) in new equity funding via a
Race Oncology 2019 Annual General Meeting Presentation
Overview of Race Oncology's new "5 path" strategy for the development of Bisantrene.
Race appoints Dr Daniel Tillett Chief Scientific Officer
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific
Race appoints Australian Clinical Program Director
Race Oncology is pleased to welcome highly experienced oncology clinical trials specialist Dr
Don't miss important updates
Get the latest news & announcement and stay up-to-date.